A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties.

ABSTRACT: Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20-30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune checkpoint target may have greater potential to enhance immune checkpoint blockade therapy. In this study, we identified an anti-PD1 monoclonal antibody, 609A, whose heavy chain can pair with a variety of light chains from different antibodies while maintaining its PD1 binding/blocking activity. Taking advantage of this property and using a linear F(ab')₂ format, we successfully produced a series of tetravalent IgG-like BsAbs that simultaneously target PD1 and other immune checkpoint

SUBMITTER: Zhao J 

PROVIDER: S-EPMC8896178 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature